Back to top

Voyager Therapeutics, Inc. (VYGR)

(Delayed Data from NSDQ)

$8.41 USD


-0.28 (-3.22%)

Updated Jan 26, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
5Strong Sell1.87%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 12% (223 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

General Information

Voyager Therapeutics, Inc.



Phone: 857-259-5340

Fax: NA



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 12/31/2020
Next EPS Date 3/2/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.56
Current Year EPS Consensus Estimate 0.87
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 3/2/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 8.69
52 Week High 14.62
52 Week Low 6.26
Beta 1.37
20 Day Moving Average 405,579.75
Target Price Consensus 13.75


% Price Change
4 Week 13.28
12 Week -14.96
YTD 26.43
% Price Change Relative to S&P 500
4 Week 9.20
12 Week -27.61
YTD 23.62
Share Information
Shares Outstanding (millions) 37.47
Market Capitalization (millions) 338.69
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) NA
Trailing 12 Months 8.69
PEG Ratio NA
EPS Growth
vs. Previous Year 653.66%
vs. Previous Quarter 1,086.96%
Sales Growth
vs. Previous Year 476.73%
vs. Previous Quarter 310.87%
Price Ratios
Price/Book 2.04
Price/Cash Flow NA
Price / Sales 1.72
12/31/20 NA
9/30/20 37.97
6/30/20 -66.46
12/31/20 NA
9/30/20 12.89
6/30/20 -17.92
Current Ratio
12/31/20 NA
9/30/20 5.14
6/30/20 3.65
Quick Ratio
12/31/20 NA
9/30/20 5.14
6/30/20 3.65
Operating Margin
12/31/20 NA
9/30/20 20.32
6/30/20 -60.61
Net Margin
12/31/20 NA
9/30/20 20.32
6/30/20 -60.61
Pre-Tax Margin
12/31/20 NA
9/30/20 20.32
6/30/20 -60.61
Book Value
12/31/20 NA
9/30/20 4.44
6/30/20 2.07
Inventory Turnover
12/31/20 NA
9/30/20 NA
6/30/20 NA
12/31/20 NA
9/30/20 0.00
6/30/20 0.00
Debt to Capital
12/31/20 NA
9/30/20 0.00
6/30/20 0.00